期刊
SCIENCE TRANSLATIONAL MEDICINE
卷 9, 期 374, 页码 1-+出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.aai9338
关键词
-
资金
- U.S. Department of Defense Breast Cancer Research Program [W81XWH0810109, W81XWH1010366]
- Susan G. Komen Postdoctoral Fellowship [PDF16376311]
- National Cancer Institute of the NIH [R01CA166422, P30CA042014]
- Oklahoma Medical Research Foundation
- Stephenson Cancer Center at the University of Oklahoma
- Huntsman Cancer Foundation
- U.S. Department of Defense (DOD) [W81XWH0810109, W81XWH1010366] Funding Source: U.S. Department of Defense (DOD)
Bone destruction occurs in aging and numerous diseases, including osteoporosis and cancer. Many cancer patients have bone osteolysis that is refractory to state-of-the-art treatments, which block osteoclast activity with bisphosphonates or by inhibiting the receptor activator of nuclear factor kB ligand (RANKL) pathway. We previously showed that macrophage-stimulating protein (MSP) signaling, which is elevated in about 40% of breast cancers, promotes osteolytic bone metastasis by activation of the MSP signaling pathway in tumor cells or in the bone microenvironment. We show that MSP signals through its receptor, RON tyrosine kinase, expressed on host cells, to activate osteoclasts directly by a previously undescribed pathway that is complementary to RANKL signaling and converges on protooncogene, non-receptor tyrosine kinase SRC (SRC). Genetic or pharmacologic inhibition of RON kinase blocked cancer-mediated bone destruction and osteoporosis in severalmouse models. Furthermore, the RON kinase inhibitor BMS-777607/ASLAN002 altered markers of bone turnover in a first-in-human clinical cancer study, indicating the inhibitor's potential for normalizing bone loss in patients. These findings uncover a new therapeutic target for pathogenic bone loss and provide a rationale for treatment of bone destruction in various diseases with RON inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据